Ironwood Pharmaceuticals Q1 2020 Earnings Report
Key Takeaways
Ironwood Pharmaceuticals reported a 16% year-over-year increase in total revenue to $80 million for the first quarter of 2020, driven primarily by U.S. LINZESS collaboration revenue of $71 million. The company delivered GAAP net income of $3 million and adjusted EBITDA of $14 million. However, due to COVID-19 uncertainties, Ironwood withdrew the remainder of its previously disclosed 2020 financial guidance, while maintaining its adjusted EBITDA guidance of >$105 million.
LINZESS total prescription demand grew by 11% year-over-year.
Total revenue increased by 16% year-over-year to $80 million, driven by U.S. LINZESS collaboration revenue of $71 million.
GAAP net income was $3 million and adjusted EBITDA was $14 million.
Maintained 2020 adjusted EBITDA guidance of >$105 million but withdrew the remainder of previously disclosed 2020 financial guidance due to COVID-19 uncertainties.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Revenue by Segment
Forward Guidance
Ironwood maintains its 2020 adjusted EBITDA guidance of >$105 million but withdraws the remainder of previously disclosed 2020 financial guidance due to COVID-19 uncertainties.